Grayscale Bitcoin Mini Trust ETF offers direct spot Bitcoin exposure with a competitive 0.15% expense ratio and robust liquidity. Click to read more on BTC.

Good morning, and welcome to Enel Capital Market Day 2026. Thank you, everyone here in the room and to people connected online. I'm here today with Enel's CEO, Mr. Flavio Cattaneo; and CFO, Mr.

SOL-1 Phase 3 superiority trial results remain masked to dateSOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular ...

Outokumpu Corporation Financial statements release February 12, 2026 at 9.00 am EET Outokumpu financial statements release 2025 - Year ended weak with headwinds in business area Europe; more favorable ...

The volume of granted export financing was record high in 2025 and also the domestic financing increased from the previous year. Finnvera granted domestic loans and guarantees amounting to EUR 1.0 ...

A fact-check finds viral chlorophyll and collagen supplements offer limited benefits. Chlorophyll lacks evidence for detox or ...

Objectives Rising patient numbers and limited resources are creating a challenging environment for healthcare providers recently. Anaesthesiologists are also increasingly faced with complex situations ...

Objectives To provide a nationwide epidemiological assessment of upper limb amputations (ULAs) in Germany, including incidence trends, underlying aetiologies, amputation levels and revision patterns, ...

Najy Nasser and Henry Watkinson of London-based HeadStart Advisers explain how their fund of hedge funds has evolved into a high-conviction, alpha-centric vehicle - one that was up in both March and ...

For gold and silver ETFs the first trading day price limits start at approximately ±6% which will expand to ±20% after ...

SG&A was $83 million for the three months ended December 31, 2025, down $9 million from the prior year period, driven by cost-saving initiatives, sustained operational efficiencies, and lower ...

Gross margin reflects one-time costs of approximately $1.9 million, or 1% for the full-year 2025, related to the FDA BLA approval of Avance ®, of which 67% are non-cash and relate to the vesting of ...